Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Apr;24(4):336-42.
doi: 10.1007/s001340050576.

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study

F Baudo  1 , T M Caimi, F de Cataldo, A Ravizza, S Arlati, G Casella, D Carugo, G Palareti, C Legnani, L Ridolfi, R Rossi, A D'Angelo, L Crippa, D Giudici, G Gallioli, A Wolfler, G Calori
Affiliations
Clinical Trial

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study

F Baudo et al. Intensive Care Med. 1998 Apr.

Abstract

Background: ATIII is decreased in sepsis and/or shock and its baseline value correlates with mortality. The efficacy of ATIII therapy on mortality was assessed in a selected group of patients admitted to the intensive care unit (ICU) in a double-blind, randomized, multicenter study.

Methods: 120 patients admitted to the ICU with an ATIII concentration < 70% were randomized to receive ATIII (total dose 24000 units) or placebo treatment for 5 days; 56 patients had septic shock.

Results: ATIII concentrations in the treated group remained constant throughout the treatment period (range 97-102%). The Kaplan-Meier analysis showed no difference in overall survival between the two groups: 50 and 46% for ATIII and placebo, respectively. Septic shock and hemodynamic support were unbalanced in the two groups at admission. Therefore the Cox analysis was carried out after adjusting for these two variables. Treatment with ATIII decreases the risk of death with an odds ratio (OR) of 0.56. Of the covariates analyzed, septic shock and the baseline multiple organ failure score were negatively associated with survival and plasma activity level was positively associated with survival with an OR of 0.97 for each 1% increase in the ATIII plasma concentration at baseline.

Conclusions: The results of ATIII treatment in this population of patients suggests that replacement therapy reduces mortality in the subgroup of septic shock patients only.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • A summary of the Japan septic disseminated intravascular coagulation study.
    Hayakawa M, Ono K. Hayakawa M, et al. Acute Med Surg. 2018 Jan 10;5(2):123-128. doi: 10.1002/ams2.326. eCollection 2018 Apr. Acute Med Surg. 2018. PMID: 29657722 Free PMC article. Review.
  • When acquired thrombophilia mattered.
    Hammond JS, Jackson L, Zaitoun AB, Rowlands BJ, Aithal GP. Hammond JS, et al. Gut. 2005 Aug;54(8):1204-5. doi: 10.1136/gut.2005.069740. Gut. 2005. PMID: 16009695 Free PMC article. No abstract available.
  • Adjunctive drug treatment in severe hypoxic respiratory failure.
    Elsasser S, Schächinger H, Strobel W. Elsasser S, et al. Drugs. 1999 Sep;58(3):429-46. doi: 10.2165/00003495-199958030-00004. Drugs. 1999. PMID: 10493271 Review.
  • Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation.
    Tagami T, Matsui H, Fushimi K, Yasunaga H. Tagami T, et al. Front Med (Lausanne). 2015 Feb 26;2:7. doi: 10.3389/fmed.2015.00007. eCollection 2015. Front Med (Lausanne). 2015. PMID: 25767801 Free PMC article.
  • The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024.
    Shime N, Nakada TA, Yatabe T, Yamakawa K, Aoki Y, Inoue S, Iba T, Ogura H, Kawai Y, Kawaguchi A, Kawasaki T, Kondo Y, Sakuraya M, Taito S, Doi K, Hashimoto H, Hara Y, Fukuda T, Matsushima A, Egi M, Kushimoto S, Oami T, Kikutani K, Kotani Y, Aikawa G, Aoki M, Akatsuka M, Asai H, Abe T, Amemiya Y, Ishizawa R, Ishihara T, Ishimaru T, Itosu Y, Inoue H, Imahase H, Imura H, Iwasaki N, Ushio N, Uchida M, Uchi M, Umegaki T, Umemura Y, Endo A, Oi M, Ouchi A, Osawa I, Oshima Y, Ota K, Ohno T, Okada Y, Okano H, Ogawa Y, Kashiura M, Kasugai D, Kano KI, Kamidani R, Kawauchi A, Kawakami S, Kawakami D, Kawamura Y, Kandori K, Kishihara Y, Kimura S, Kubo K, Kuribara T, Koami H, Koba S, Sato T, Sato R, Sawada Y, Shida H, Shimada T, Shimizu M, Shimizu K, Shiraishi T, Shinkai T, Tampo A, Sugiura G, Sugimoto K, Sugimoto H, Suhara T, Sekino M, Sonota K, Taito M, Takahashi N, Takeshita J, Takeda C, Tatsuno J, Tanaka A, Tani M, Tanikawa A, Chen H, Tsuchida T, Tsutsumi Y, Tsunemitsu T, Deguchi R, Tetsuhara K, Terayama T, Togami Y, Totoki T, Tomoda Y, Nakao S, Nagasawa H, Nakatani Y, Nakanishi N, Nishioka N, Nishikimi M, Noguchi S, Nonami S, Nomura O, Hashimoto K, Hatakeyama J, Hamai Y, Hikone M, Hisamune … See abstract for full author list ➔ Shime N, et al. Acute Med Surg. 2025 Feb 24;12(1):e70037. doi: 10.1002/ams2.70037. eCollection 2025 Jan-Dec. Acute Med Surg. 2025. PMID: 39996161 Free PMC article.
See all "Cited by" articles

References

    1. Thromb Res. 1982 Aug 1;27(3):271-8 - PubMed
    1. Intensive Care Med. 1998 Jul;24(7):663-72 - PubMed
    1. Thromb Haemost. 1993 Feb 1;69(2):98-102 - PubMed
    1. Crit Care Med. 1989 Aug;17(8):724-33 - PubMed
    1. Crit Care Med. 1984 Nov;12(11):975-7 - PubMed

Substances

LinkOut - more resources